Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

NCT06592599 | Recruiting Phase 2 FDA Drug FDA Device

• 2 other identifiers: IRB-75587NCI-2025-00939
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.

Conditions

Nasopharyngeal Carcinoma

Keywords

gemcitabine; docetaxel; toripalimab

Outcome Measures

Primary Outcomes (2)

• Induction chemotherapy completion rate

  Induction chemotherapy completion rate, defined as the proportion of patients who complete three cycles of chemoimmunotherapy within 12 weeks of initiation. Completion is defined for induction as receiving all 3 cycles as planned, including protocol specified dose reduction and delays. .

  3 years

• Radiation completion rate

  Radiation completion rate, defined as the proportion of patients who complete specified radiation within 8 weeks of radiation initiation. Radiation completion is defined as completion of planned doses of radiation.

  3 years

Secondary Outcomes (2)

• Overall Response (ORD) rate following induction

  3 years

• Complete Response (CR) rate following radiation

  3 years

Study Arms (1)

Gemcitabine, Docetaxel and Capecitabine

EXPERIMENTAL

Patients will receive three q 21-day cycles of gemcitabine 1000 mg/m2 plus docetaxel 75 mg/m2 plus toripalimab 240 mg, followed by radiation to 70 Gy plus concurrent weekly cisplatin, 40 mg/m2 up to 7 doses, followed by adjuvant capecitabine 650 mg/m2 BID for one year plus toripalimab 240 mg q 21 days for 9 doses.

Drug: Toripalimab; Radiation: Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation

Interventions

Toripalimab DRUG

Toripalimab will be administered 240 mg intravenously every three weeks in combination with the induction chemotherapy regimen for 3 cycles, and for 9 cycles as adjuvant treatment following radiation as specified in the overall sequential treatment plan.

Gemcitabine, Docetaxel and Capecitabine

Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation RADIATION

Radiation treatment will be initiated 3-6 weeks following day 1 of the last induction cycle using institutional standards of care and support as follows: Intensity modulated radiotherapy, 70 Gy in 33 fractions M-F once daily plus cisplatin 40 mg/m2 IV weekly for up to 7 doses. Following the completion of concurrent chemoradiation, capecitabine will be administered using institutional standards of care as follows: Capecitabine 650 mg/m2 PO BID x 12 months beginning 12 to 16 weeks following the end of radiation treatment. Dose reductions and discontinuance of capecitabine will be according to the standard of care applied at the treating institution. Adjuvant Toripalimab 240 mg IV q 21d x 9 maximum doses will be initiated concurrently with the initiation of adjuvant capecitabine, beginning 12-16 weeks following the end of radiation.

Gemcitabine, Docetaxel and Capecitabine

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Eligible disease(s) / stage(s): Locoregionally advanced EBV positive NPC (T3-4, any N OR any T, N1-3. No M1) per AJCC v 8
• Prior therapy: None for NPC permitted
• Life expectancy: 3 months at least
• Contraception requirements: Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control during treatment with toripalimab and for 4 months after the last dose.
• ECOG Performance Status of 0,1, or 2
• Age: At least 18 years old.
• CBC/differential obtained within 21 days prior to day 1 of treatment, with adequate bone marrow function defined as follows:
• Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3
• Platelets ≥ 100,000 cells/mm3;
• Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.);
• Adequate hepatic function within 21 days prior to day 1 of treatment, defined as follows:
• Total bilirubin ≤ 1.5 x institutional ULN;
• AST and ALT ≤ 1.5 x institutional ULN;
• Adequate renal function within 21 days prior to day 1 of treatment, defined as follows:
• Serum creatinine ≤ 1.5 mg/dl or calculated or measured creatinine clearance (CC) ≥ 50 ml/min

You may not qualify if:

• Prior systemic anticancer treatment for NPC
• Prior radiation to head and neck region or regions necessitating overlapping fields
• Concurrent use of any anti- cancer treatment, standard, alternative or investigational.
• History of allergic reactions to any agents in this study
• Autoimmune disease or organ transplant which in the judgment of the PI would increase the risk of immune checkpoint inhibition.
• Pregnant or breastfeeding
• Severe, active co-morbidity, defined as follows:
• Major medical or psychiatric illness, which in the investigator's opinion would interfere with the completion of therapy and follow up or with full understanding of the risks and potential complications of the therapy;
• Unstable angina and/or uncontrolled congestive heart failure within past 6 months;
• Myocardial infarction within the last 6 months;
• Current acute bacterial or fungal infection requiring intravenous antibiotics; note that patients receiving IV antibiotics or currently on oral antibiotics whose infection is assessed to be adequately treated or controlled are eligible.
• Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to day 1 of treatment;
• Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive
• Patients with hearing loss assessed to be primarily sensorineural in nature, requiring a hearing aid, or intervention (i.e. interfering in a clinically significant way with activities of daily living); a conductive hearing loss that is tumor-related is allowed
• ≥ grade 2 peripheral sensory neuropathy

Sponsors & Collaborators

• Stanford University: lead

Study Sites (1)

Stanford University

Palo Alto, California, 94304, United States

RECRUITING

MeSH Terms

Conditions

Nasopharyngeal Carcinoma

Interventions

toripalimab

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Nasopharyngeal Neoplasms; Pharyngeal Neoplasms; Otorhinolaryngologic Neoplasms; Head and Neck Neoplasms; Neoplasms by Site; Nasopharyngeal Diseases; Pharyngeal Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases

Study Officials

• A. Dimitrios Colevas, MD

  Stanford University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Elizabeth Winters

CONTACT

(650) 723-6372; ewinters@stanford.edu

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 9, 2024
• First Posted: September 19, 2024
• Study Start: September 3, 2024
• Primary Completion (Estimated): January 1, 2029
• Study Completion (Estimated): January 1, 2029
• Last Updated: February 10, 2026

Record last verified: 2026-02

Locations

US (1)